Gilmartin steps down as Merck chief executive

Raymond Gilmartin has stepped down as chief executive of Merck, effective immediately, the company announced this morning in a conference call with investors.
The company's board of directors has elected Merck manufacturing division president Richard Clark to replace Gilmartin.
Clark, 59, began his career at Merck in 1972 as a quality control inspector.
He progressed through a series of increasingly responsible roles in the areas of production, new products planning, and strategic planning, becoming senior vice president, North American operations, in 1996.
Clark has held high-level executive positions at Medco Health Solutions, the pharmacy benefits management (PBM) company where he served as president from 2000 to June 2002, when he was named chairman and chief executive officer. Clark remained in that position until March 2003.
Gilmartin, who served as president and chief executive since 1994 will remain with Merck as a special advisor until March 2006, when he is scheduled to retire.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.